Etoposide

For research use only.

Catalog No.S1225 Synonyms: VP-16, VP-16213

149 publications

Etoposide Chemical Structure

CAS No. 33419-42-0

Etoposide (VP-16, VP-16213) is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity. Etoposide induces autophagy, mitophagy and apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Etoposide has been cited by 149 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Etoposide (VP-16, VP-16213) is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity. Etoposide induces autophagy, mitophagy and apoptosis.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly M3[0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXnTWM2OD1yLkGy5qCKyrIkgJmwMlAyKM7:TR?= NEL2fIMzPTl4MEK4Ni=>
KellyCis83 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\KTWM2OD1yLkG25qCKyrIkgJmwMlAzKM7:TR?= M37qXVI2QTZyMkiy
SK-N-AS NFThdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnrTWM2OD1yLkK05qCKyrIkgJmwMlA{KM7:TR?= M{jSW|I2QTZyMkiy
SK-N-ASCis24 NVPJcpNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PHVWlEPTB;MD61O-KBkcLz4pEJNE4yOSEQvF2= NELCbowzPTl4MEK4Ni=>
U87 Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnZZ2ExNTVyIN88US=> NFzlVHI1QCCq NH\ueGVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IIPpcIljcW6rbh?= MWWyOVc2ODJ5Mx?=
HCT116 NFTIeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXONE42NTJwNTFOwG0> MUK0POKhcMLi NVPrcGJIUUN3ME2xMlc{yqEEsdMgNE4zOcLizszN NX3kU4NuOjV5NE[3OlM>
HT-29 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv0O2ZNOC53LUKuOUDPxE1? M2rCdFQ5yqCqwrC= MnXxTWM2OD15LkNCpOKyyqBzLkC0xsDPxE1? MojxNlU4PDZ5NkO=
Caco2 MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O5TlAvPS1{LkWg{txO MmnsOFjDqGkEoB?= Mlv5TWM2OD15LkK2xsDDucLiMT62POKh|ryP MWCyOVc1Pjd4Mx?=
COLO 205 M4W2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKzfGQxNjVvMj61JO69VQ>? NU\4XolDPDkEoHlCpC=> NITyUFJKSzVyPUGuOlHDqMLzwrCwMlAzyqEQvF2= NGCySHMzPTd2Nke2Ny=>
SW480 NEDTR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT3NE42NTJwNTFOwG0> MkHEOFjDqGkEoB?= MlLxTWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP MkS4NlU4PDZ5NkO=
HEK293T M2e5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnQNU02KM7:TR?= MlOzOFjDqGkEoB?= Mn3ETWM2OD1{LkSyxsDDucLiMD6wOeKh|ryP MV[yOVc1Pjd4Mx?=
Hep3B  NFHP[GhHfW6ldHnvckBCe3OjeR?= M2fCOVExKM7:TR?= NWHXWoNtPDkEoHlCpC=> Mnq5doVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> NFm3d5YzPTZ|M{W2OC=>
Hep3B  NVHUU5NqTnWwY4Tpc44hSXO|YYm= M3ezW|AvOS1zMDFOwG0> NFfmXnIzPCCq M{DIU5N2eHC{ZYPz[ZMhfGinIHX4dJJme3Orb36gc4YhcGWyY3nkbY4hdVKQQR?= NIDYdYwzPTZ|M{W2OC=>
HEK293 NXTQTW5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnyTWM2OD15LkG0xsDDucLiMD6zOuKh|ryP NHjoRVAzPTZyM{GyNi=>
DU145 NG\YdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PrUmlEPTB;Mj6yPOKhyrIEoECuNFTDqM7:TR?= NYLN[2VOOjV4MEOxNlI>
HCT15 MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfWTWM2OD1yLkixxsDDucLiMD6wNeKh|ryP NE\oNHozPTZyM{GyNi=>
T47D NEXvcINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwMUlCpOKyyqByLkGxxsDPxE1? M1;LeVI2PjB|MUKy
SMMC-7721 MkDJSpVv[3Srb36gRZN{[Xl? MnrwOFAh|ryP NYfyc5E1PDhiaB?= NHvsfJRFVVOR MXHpcoR2[2W|IN8zTFJCYCCob3PpJIZwem2jdHnvci=> NIXEd4czPTV2NEO2NS=>
MDA-MB-231 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjwelI4PzMEoHi= MVnJR|UxRTJzLkNCpOKyyqB2LkNCpO69VQ>? NHm5eoIzPTR6NkKxPS=>
MCF-7 M3vIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1voRVczyqCq NUfsXHdoUUN3ME2xNE46yqEEsdMgNk4yyqEQvF2= MUmyOVQ5PjJzOR?=
Jurkat NYDMRWFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n2PFczyqCq NVjSfZRCUUN3ME2xMlLDqMLzwrCxMlXDqM7:TR?= MorxNlU1QDZ{MUm=
HeLa MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i5XlczyqCq MoLrTWM2OD1|LkpCpOKyyqB{LkRCpO69VQ>? NX\2VpRqOjV2OE[yNVk>
MCF7  M2n3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrZNJU2NTFyMDFOwG0> MkLmO{Bl NGfvWVdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYSyOVQ4OjZzOR?=
K562 M1;MdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXpVmlRPzMEoHi= NV[2eJJQUUN3ME2wMlI6yqEQvF2= MnnjNlUzQDJ4NUO=
K/VP.5 MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln6O|LDqGh? Mn;iTWM2OD12LkpCpO69VQ>? M3vKN|I2Ojh{NkWz
SH-EP  MWfGeY5kfGmxbjDBd5NigQ>? NV;HeIFOOjEEoN88[{9udA>? MVGyOOKhcA>? MXnpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[g[Y5ld2enbn;1d{BFTVCS MVqyOVI3OTl6MR?=
SCC25 NXnqU5RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\PNGIzPMLiaB?= M2rYVmlEPTB;NEOuN:KhyrIEoEGuNVLDqM7:TR?= M3zOV|I2OjJyN{K5
CAL27 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPkXGczPMLiaB?= M17nXGlEPTB;NUKuNeKhyrIEoEGuNFnDqM7:TR?= NHz1cW4zPTJ{MEeyPS=>
FaDu NXvuV3lET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i2cFI1yqCq Mne1TWM2OD1{NT64PeKhyrIEoEGuNVPDqM7:TR?= M3r4b|I2OjJyN{K5
SCC25 NYHoRZlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHVS5U1QMLiaB?= NX7ZSpRkUUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> MnPWNlUzOjB5Mkm=
CAL27 M1[0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LRN|Q5yqCq NH\2RXBKSzVyPUG4MlI1yqEEsdMgNU4yPcLizszN MYGyOVIzODd{OR?=
FaDu MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[2OFjDqGh? Mnq1TWM2OD14LkSzxsDDucLiMT6xN:Kh|ryP NH3JZZIzPTJ{MEeyPS=>
SCC25 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXKO|LDqGh? MWDJR|UxRThwNEJCpOKyyqBzLkGxxsDPxE1? NUX0UIxqOjV{MkC3Nlk>
CAL27 MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LjOFczyqCq MoT0TWM2OD12LkK3xsDDucLiMT6xOOKh|ryP MorZNlUzOjB5Mkm=
FaDu NV\tO3FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTjO|LDqGh? NFvHd|NKSzVyPUWuNFLDqMLzwrCxMlE2yqEQvF2= NVPZVYRGOjV{MkC3Nlk>
MCF-7 M{LoZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXS0POKhcMLi M1XEeWROW09? NVXFZVRtUUN3ME23MlLDqMLzwrCwMljDqM7:TR?= M{HKRlI2OjF4M{e4
T-47D NF\EZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV20POKhcMLi NHjEWWtFVVOR NHrkOpJKSzVyPUeuO:KhyrIEoECuO:Kh|ryP NHrPNGMzPTJzNkO3PC=>
MDA-MB-231 NYXuO3lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWC0POKhcMLi M4XpU2ROW09? MlLtTWM2OD1zMj64xsDDucLiMT6wxsDPxE1? M2\TOVI2OjF4M{e4
DU145 Mnn3RZBweHSxc3nzJGF{e2G7 M3rm[lExNTFyMDFOwG0> NYnaOpd[QCCq Mn7ZSG1UVw>? NGHzV4ZqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= NGnQdJUzPTF2OU[4NS=>
DU145 stem-like NFjjbVVCeG:ydH;zbZMhSXO|YYm= NFX6VmcyOC1zMECg{txO NWq3fW5SQCCq NU[3XXRCTE2VTx?= M3LVc4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NH\oc|MzPTF2OU[4NS=>
DU145 NXTMVIhoTnWwY4Tpc44hSXO|YYm= MYSxNE0yODBizszN MXyyJIg> NV3BcIhtTE2VTx?= MUTpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVvpWotpOjVzNEm2PFE>
DU145 stem-like NEm3[mdHfW6ldHnvckBCe3OjeR?= NEHZRWUyOC1zMECg{txO NYnhSpVWOiCq NWWybJZ4TE2VTx?= NWLzdWVUcW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnLrNlUyPDl4OEG=
UW228-3 M2PiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPV[|NHOC5yMT2zNFAh|ryP MlHPOFghcA>? NYTXTWhtTE2VTx?= MojxTWM2OD1yLkm5xsDPxE1? M2eyV|I2OTF7MUi1
NSCs NYjDU4VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\VSm4xNjBzLUOwNEDPxE1? M{TTSFQ5KGh? NHnX[mNFVVOR NH;jSZBKSzVyPUCuN{0{yqEQvF2= M3qwS|I2OTF7MUi1
MKL-1  NEPLeIZHfW6ldHnvckBCe3OjeR?= MkmwNVAuOTByMDDuUS=> MkLKOEBl MV7pcoR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiTVjDMWkh\XiycnXzd4lwdg>? NUn5UGdVOjVzMU[3OVQ>
MCF7 EV MmfaSpVv[3Srb36gRZN{[Xl? MUOxNE0yODBizszN MonRNwKBkWh? M{GzR4lv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ M4X6WVI2ODh6MkCz
MCF 7BMI1 NX3I[ll2TnWwY4Tpc44hSXO|YYm= NYTqWpFyOTBvMUCwJO69VQ>? MYqy5qCKcA>? Mn;WbY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> NHG4Tm0zPTB6OEKwNy=>
MCF7 EV NHvselJHfW6ldHnvckBCe3OjeR?= Mlm4NVAuOTByIN88US=> MYOy5qCKcA>? NY\5fnRTTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v NGjVWlYzPTB6OEKwNy=>
MCF7 BMI1 MmTRSpVv[3Srb36gRZN{[Xl? NInB[3oyOC1zMECg{txO NUnSemNtOuLCiXi= MWnFWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= NWe1O4poOjVyOEiyNFM>
HepG2 NU\yN4toT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLvdZhFVVORwrC= NXzpSlRPUUN3ME2zNE4yPsLiwsJCpFAvPTEEoN88US=> MkC0NlUxPzh|MUG=
MOLT-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{SxWWROW00EoB?= MnL5TWM2OD1yLkC1NeKhyrIEoECuNFAzyqEQvF2= NGXWUHYzPTB5OEOxNS=>
HT1080 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHs[pA{OS1zMECg{txO MVm0M|I1NzR6IHi= MorBSG1UV8Li MmT1bY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w MnzlNlUxPzhyNkS=
HT1080 Mn;CSpVv[3Srb36gRZN{[Xl? NHe3V3kxNjByMEGtNVAxKM7:TR?= MXSxMVI1KGh? NEfEUmtFVVORwrC= NUPTRodwcW6mdXPld{BxNXB3Mzjz[ZIyPSliaX6gZo91cCC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy M4PCeFI2ODd6ME[0
HT1080 M2XFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3YeI4xNjByMEGtNVAxKM7:TR?= NV7QUFhwOjRiaB?= MnHGSG1UV8Li MVfjZZV{\XNiYX6gbY5kemWjc3WgbY4hfGinIH71cYJmeiCxZjDj[YxteyCrbjDHNk9ONCC5aHns[UBl\WO{ZXHzbY5oKFNiYX7kJGcyKHCqYYPlJINmdGy| NUXiVWtUOjVyN{iwOlQ>
HD-MY-Z MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ja[FI1NzR6L{eyJIg> MkX4TWM2OO,:nkGwNEDPxE1? NFjqZZEzPTB2OEKzOi=>
DOHH-2 NHHiWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK4TXBIOjRiaB?= M3;3WGlEPTExvK6xNFAh|ryP Ml7wNlUxPDh{M{[=
DOHH-2 MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz0OFghcA>? MlLZTWM2OD1zOT65xsDPxE1? Mn;nNlUxPDh{M{[=
DOHH-2 NYi4bYNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf1TGs4OiCq NYHIXFhsUUN3ME21xsDPxE1? NF3iTmczPTB2OEKzOi=>
REH MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEezeFEzPCCq NULXXWNbUUN3ME2wMlAzP8LizszN M2Gy[lI2ODR6MkO2
REH NIHI[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrT[3MxPDhiaB?= Ml3TTWM2OD1yLkCxOOKh|ryP MlnVNlUxPDh{M{[=
REH MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELmZnQ4OiCq NIfyVFNKSzVyPUCuNFE2yqEQvF2= NF3C[WIzPTB2OEKzOi=>
HH NVvZd3VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUm1PZp5OjRiaB?= M3PyTWlEPTB;MUC0MlfDqM7:TR?= MWiyOVA1QDJ|Nh?=
HH MmDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\xOFghcA>? M3r5dGlEPTB;NEiuOuKh|ryP NWTBXmlYOjVyNEiyN|Y>
HH NInzPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nJ[FczKGh? M4CwdGlEPTB;MUSuO:Kh|ryP MlywNlUxPDh{M{[=
HuT-78 NFHDR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSyOEBp MonZTWM2OD17LkRCpO69VQ>? M2mxNlI2ODR6MkO2
HuT-78 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHNWIQ3PDhiaB?= NXL5V2FPUUN3ME20MlPDqM7:TR?= NWjCR|lSOjVyNEiyN|Y>
HuT-78 NXrQbGY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:3NkBp M{nydGlEPTB;ND6yxsDPxE1? M4nYSVI2ODR6MkO2
OPM-2 M4rMOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC0TpgzPCCq M3PYUmlEPTB;MkSuNeKh|ryP MkTQNlUxPDh{M{[=
OPM-2 NU\TSmI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHizUJU1QCCq NEn5WY9KSzVyPUVCpO69VQ>? NH;CUY0zPTB2OEKzOi=>
OPM-2 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfOUWs4OiCq MkK0TWM2OD1zLkRCpO69VQ>? M1\0S|I2ODR6MkO2
RPMI-8226 M3TBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{THNlI1KGh? Mnf0TWM2OD1zME[uOuKh|ryP Mlv3NlUxPDh{M{[=
RPMI-8226 M1XoWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVq0PEBp M1fNdmlEPTB;OUGuNeKh|ryP MnfINlUxPDh{M{[=
RPMI-8226 MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3WSW1EPzJiaB?= M4HrNWlEPTB;MUSuPeKh|ryP M37lV|I2ODR6MkO2
U-266 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLZbYlWOjRiaB?= MnfQTWM2OD16Nj6yxsDPxE1? NWLKeId7OjVyNEiyN|Y>
U-266 NXjReY1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXN[XV5PDhiaB?= NEDyd3BKSzVyPU[4MlTDqM7:TR?= MXqyOVA1QDJ|Nh?=
U-266 NUfRZWJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL3dIQ4OiCq MU\JR|UxRTJ5LkVCpO69VQ>? NWqxTZp5OjVyNEiyN|Y>
Kelly NUXtOHZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\BV40xNTFyIN88US=> Mm\GO|LDqGh? MXXJR|UxRTFwNUG4xsDPxE1? M3HrclI2ODB6OUCw
SH-SY5Y  MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHWNE0yOCEQvF2= MnzCO|LDqGh? NHvzcWJKSzVyPUCuO|U1yqEQvF5CpC=> Mn21NlUxODh7MEC=
SK-N-AS NUHjUoRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{OzW|AuOTBizszN M1PkSFczyqCq M1jRNGlEPTB;MT63NVLDqM7:TdMg MoDtNlUxODh7MEC=
SK-N-DZ NXmwSWVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHvPYYxNTFyIN88US=> NEXDNVE4OsLiaB?= NGG2e4xKSzVyPUWuOFg2yqEQvF2= NEHpToYzPTByOEmwNC=>
HepG2 NInrUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;TVHo1QMLiaB?= M3q3XWROW00EoB?= M{H2O2lEPTB;MUOuOlXDqMLzwrCwMlkzyqEQvF2= M17xUVI1QTl4MUO2
A549 NYDUUoVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO0POKhcA>? NVzyenZZTE2VT9Mg MVLJR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= NUXNcJpHOjR7OU[xN|Y>
MCF7 MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjwdZY1QMLiaB?= MWHEUXNQyqB? NIfJWGlKSzVyPUixMlA6yqEEsdMgNVQvOjIEoN88US=> NH[3NXEzPDl7NkGzOi=>
HL-60  MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\IW4d4PzMEoHi= NULhRWYzUUN3ME2wMlEz6oDHzszN NYnhbohTOjR7OUOwNVQ>
HL-60[R] MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XoV|czyqCq NH\hdZBKSzVyPUOuNVLjiIYQvF2= Ml7JNlQ6QTNyMUS=
MIAPACA MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\ITVhIUTVyPUGuN{DDuSByLkCzJO69VQ>? M3u0flI1QTV|OEKx
MCF-7 M1P1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULEb3EzT0l3ME2wMlI2KMLzIECuNUDPxE1? NH\UWmkzPDl3M{iyNS=>
HeLa NYD6endWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLxS2k2OD1yLk[0JOKyKDBwNDFOwG0> NFexbYMzPDl3M{iyNS=>
MO59K  MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV23JIQ> MUXJR|UxRTBwMUhihKXPxE1? NU[wbZJ5OjR7NUO1OlE>
MO59J M3HD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULPcnpbPyCm MlX1TWM2OD1yLkJihKXPxE1? M2HqRlI1QTV|NU[x
ME 180 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jPZlQ5yqCqwrC= MV3JR|UxRThwOdMgxtHDqDBwM,MAie69VQ>? NUjESWVJOjR7NUOwNlc>
MCF-7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXy0POKhcMLi M3LBcWlEPTB;MkOuPUDDuSByLkRihKXPxE1? NWG2bG1qOjR7NUOwNlc>
HeLa M{PNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUS0POKhcMLi NVjseWdDUUN3ME20MlcyKMLzIEGuOQKBjc7:TR?= MojJNlQ6PTNyMke=
MDA-MB-453 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjXblZYPDkEoHlCpC=> M1TrWmlEPTB;MUKuOUDDuSByLki15qCG|ryP NIHYenYzPDl3M{CyOy=>
MDA-MB-231 MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDQTWh3PDkEoHlCpC=> MX;JR|UxRTJ2LkKyJOKyKDJwOUVihKXPxE1? MnXwNlQ6PTNyMke=
PC-3 M1LCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUToWG5uPDkEoHlCpC=> NU\iWmFIUUN3ME2xOE41KMLzIEOuNlPjiIYQvF2= NETNRlAzPDl3M{CyOy=>
HT-29 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC3OFjDqGkEoB?= MXnJR|UxRTJzLkS1JOKyKDNwOEhihKXPxE1? MUKyOFk2OzB{Nx?=
BGC-823 NF;L[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm0POKhcMLi MYnJR|UxRTR|Lke0JOKyKDVwMURihKXPxE1? MnSwNlQ4QTN6N{e=
HeLa MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu0POKhcMLi MXzJR|UxRTJyOT65NEDDuSBzMz60NkDjiIYQvF2= NGPYW|QzPDd7M{i3Oy=>
A549 NEHnb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPGOFjDqGkEoB?= NEixemVKSzVyPUGzPU42PCEEsTC3MlA26oDHzszN M2m4VlI1Pzl|OEe3
HK-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDlNXZXPDkEoHlCpC=> NWmzU5JtUUN3ME25MlE4KMLzIEGuOVjjiIYQvF2= MXWyOFc6Ozh5Nx?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
- Collapse

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
- Collapse
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213
Smiles CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID